Evidence map›Paper›PMID 29731665›Full record

ArticleCancer management and research2018

Elevated circulating miR-182 acts as a diagnostic biomarker for early colorectal cancer.

Xiangxiang Liu, Tao Xu, Xiuxiu Hu, XiaoXiang Chen, Kaixuan Zeng, Li Sun, Shukui Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Novel Diagnostic Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiangxiang LiuCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Tao XuCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Xiuxiu HuCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
XiaoXiang ChenCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Kaixuan ZengCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Li SunCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Shukui WangCentral Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlobally, colorectal cancer (CRC) is one of the most common cancers with high mortality. Although CRC patients in stages I-II are curable after surgical resection, due to the lack of sensitive and specific biomarkers, many patients are in the advanced stages when diagnosed. This study aimed to investigate whether circulating miRNAs in plasma could act as biomarkers for early CRC diagnosis. PATIENTS AND

methodsAll healthy subjects and patients were from Nanjing First Hospital. We first selected 2 differential miRNAs by integrated analysis of 4 Gene Expression Omnibus (GEO) data sets and The Cancer Genome Atlas (TCGA) database. Next, the expression of these 2 miRNAs in tissue and plasma samples were examined through quantitative real-time polymerase chain reaction. Training phase and validation phase were designed to investigate the diagnostic utility of these differential miRNAs using receiver operating characteristic (ROC) curve analysis.

resultsAfter integrated analysis of 4 GEO and TCGA databases, upregulated miR-182 and miR-20a were selected to further investigate their diagnostic potential for CRC. We discovered that miR-182 and miR-20a were upregulated in CRC tissue and plasma and that circulating miR-182 and miR-20a in the plasma of CRC patients were tumor derived. The area under the ROC curve (AUC) of circulating miR-182 was 0.929 (95% CI 0.875-0.983) in the training phase and 0.891 (95% CI 0.821-0.961) in the validation phase. The AUC of circulating miR-20a expression was 0.801 (95% CI 0.695-0.906) in the training phase and 0.736 (95% CI 0.631-0.842) in the validation phase.

conclusionCirculating miR-182 is a novel potential biomarker for early CRC diagnosis.

Indexed as

biomarkercolorectal cancerGEO databasemiRNAsTCGA database

Identifiers

PMID29731665
PMCPMC5927061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.